Cannara Biotech Inc. (LOVE.V)
| Previous Close | 0.8500 |
| Open | 0.8400 |
| Bid | 0.8400 x N/A |
| Ask | 0.8700 x N/A |
| Day's Range | 0.8400 - 0.8400 |
| 52 Week Range | 0.7500 - 1.1500 |
| Volume | |
| Avg. Volume | 21,475 |
| Market Cap | 75.616M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | 8.40 |
| EPS (TTM) | 0.1000 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
News DirectCannara Biotech CFO Nicholas Sosiak: Unveiling Success Strategies and Future Plans
Cannara Biotech Inc CFO Nicholas Sosiak joined Steve Darling from Proactive to provided valuable insights into the company's success in the cannabis industry.
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Key Takeaways; Psychedelic Sector Below is a weekly roundup on the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends. Top […]
CNW GroupCannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion
Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced its fiscal first quarter 2024 financial and operating results for the three month period ended November 30, 2023.
